文献速递技术与安全腹部泌尿生殖PETCT

氟脱氧葡萄糖PET-CT偶然局灶性摄取的循证管理

Evidence-based management of incidental focal uptake of fluorodeoxyglucose on PET-CT.
PubMed 文献 · Br J Radiol · 2018-01-31

本文综述氟脱氧葡萄糖PET/CT上偶然发现局灶性摄取(伴或不伴CT异常)的恶性发生率、鉴别诊断及影像标准,按器官给出具体建议:垂体SUVmax>4.1需进一步检查、甲状腺全部检查、乳腺全部检查、肺实质无CT结节则无需进一步检查、结肠SUVmax>5.9需检查且SUVmax>11.4需紧急检查、肾上腺依患者有无癌症而定、前列腺对>50岁男性或>40岁伴外周摄取或其他危险因素者需检查;腮腺、鼻口咽、食管、胰腺、子宫和卵巢有部分证据;肝、脾、肾、胆囊、睾丸和骨证据不足。

要点

  • 垂体局灶性摄取SUVmax>4.1时需进一步检查。
  • 甲状腺和乳腺的局灶性摄取均需进一步检查。
  • 肺实质局灶性氟脱氧葡萄糖摄取而无CT结节时无需进一步检查。

核心结论

  • 本文按器官总结了氟脱氧葡萄糖PET/CT偶然局灶性摄取的循证管理建议,部分器官有足够证据给出具体建议,部分器官证据有限或不足。

研究设计与样本

  • 本文为综述,纳入证据包括系统评价和Meta分析至几乎无证据,证据强度差异很大;未报告检索范围、纳入文献数量或中心数。

诊断标准与关键数值

  • 垂体:SUVmax>4.1时需进一步检查。
  • 甲状腺:所有局灶性摄取均需进一步检查。
  • 乳腺:所有局灶性摄取均需进一步检查。
  • 肺实质:氟脱氧葡萄糖局灶性摄取而无CT结节时,无需进一步检查。
  • 结肠:SUVmax>5.9的局灶性摄取需进一步检查,SUVmax>11.4时需紧急检查。

临床应用与阅片要点

  • 由于患者间和机构间观察到的SUV变异,使用其他研究报告的标准化摄取值(SUV)时需谨慎。
  • 腮腺、鼻口咽、食管、胰腺、子宫和卵巢有部分证据可指导进一步管理。
  • 肝、脾、肾、胆囊、睾丸和骨的证据不足以指导管理,患者特征和其他指南可能对决定进一步管理更有用。

局限性

  • 证据基础强度差异很大,从系统评价和Meta分析至几乎无证据。
  • 使用其他研究报告的标准化摄取值(SUV)时需谨慎,因患者间和机构间观察到SUV变异。
  • 肝、脾、肾、胆囊、睾丸和骨的证据不足以指导管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Focal incidental uptake, with or without CT abnormalities, is a common finding on fluorodeoxyglucose PET/CT and evidence-based management for this type of uptake is lacking. This article reviews the evidence on focal incidental uptake including the incidence of malignancy, differential diagnosis and imaging criteria which can be used to further characterize it. The article focusses on PET rather than CT criteria. The strength of the evidence base is highly variable ranging from systematic reviews and meta-analyses to a virtual absence of evidence. Caution needs to be used when using standardized uptake values (SUVs) reported in other studies due to interpatient and institution observed variation in SUVs. There is sufficient evidence to permit specific suggestions on how to interpret the foci and recommend further management in the: pituitary (investigate when SUVmax >4.1), thyroid (investigate all), breast (investigate all), lung parenchyma (if focus of fluorodeoxyglucose without a CT nodule, no further investigations), colon (investigate all foci with SUVmax >5.9, urgently if SUVmax >11.4), adrenals (criteria depend on if patient has cancer) and prostate gland (investigate in males aged >50 years or >40 years if peripheral uptake or patient has other risk factors). There is some evidence to guide further management for the parotid gland, naso-orophaynx, oesophagus, pancreas, uterus and ovaries. There is insufficient evidence to guide management for the liver, spleen, kidneys, gallbladder, testis and bone, for these organs patient characteristics and other guidelines will likely be of more use in determining further management.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Pencharz D, Nathan M, Wagner TL, et al. Evidence-based management of incidental focal uptake of fluorodeoxyglucose on PET-CT. Br J Radiol. 2018. PMID: 29243502. doi:10.1259/bjr.20170774

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。